PIRS Overview

Pieris Pharmaceuticals Announcement: Pieris Pharmaceuticals has approved a significant increase in authorized shares and the 2024 Equity Incentive Plan during a special stockholder meeting, alongside finalizing a merger with Palvella Therapeutics which will lead to a name change.

Company Overview: Operating in the biotechnology sector, Pieris focuses on developing therapeutic proteins, currently holds a market cap of $21.92M, and has a year-to-date price performance of 14.01%.

Investigation of Mergers: Halper Sadeh LLC is investigating several companies, including Kidpik Corp., ACNB Corporation, Pieris Pharmaceuticals, and Blue Owl Capital Corporation, for potential violations of federal securities laws related to their mergers.

Shareholder Rights: The law firm encourages shareholders from these companies to contact them for information on their legal rights and options regarding the proposed transactions.

Investigation of Companies: Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches related to mergers involving Cyclo Therapeutics, BurTech Acquisition Corp., Pieris Pharmaceuticals, and CrossFirst Bankshares.

Shareholder Rights: The firm encourages shareholders from these companies to contact them for free consultations regarding their legal rights and options, emphasizing that they operate on a contingent fee basis.

Investigation of Merger: Former Louisiana Attorney General Charles C. Foti, Jr. and Kahn Swick & Foti, LLC are investigating the proposed merger between Pieris Pharmaceuticals, Inc. and Palvella Therapeutics, Inc., focusing on the fairness of the transaction for Pieris shareholders.

Contact Information: Interested parties can discuss their legal rights regarding the merger with KSF at no cost, through email or phone, and further information is available on their website.

Financial Performance: Pieris Pharmaceuticals Inc. reported a loss of $2.9 million in its third quarter, equating to a per-share loss of $2.19.

Source of Information: The report was generated by Automated Insights using data from Zacks Investment Research.

Clinical Trial Announcement: Palvella Therapeutics has initiated a Phase 3 clinical trial (SELVA) for QTORIN™ 3.9% rapamycin anhydrous gel, targeting microcystic lymphatic malformations, with the first patient now dosed and enrollment ongoing at various U.S. centers.

Potential Impact: If successful, QTORIN™ rapamycin could become the first FDA-approved treatment for microcystic LMs, addressing a significant unmet medical need for over 30,000 patients in the U.S. suffering from this debilitating genetic condition.